Lung Cancer - LLC Cells

Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic

Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapies, compared to SCLC. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.

In 2016, pembrolizumab became the first immunotherapy to be used as a first line in the treatment of NSCLC if the cancer overexpressed PDL1 and the cancer has no mutations in EGFR or in ALK. The prognosis of patients with NSCLC improved significantly with the introduction of immunotherapy options. Continued research into other immuno-oncology options for NSCLC can only improve patient options and outcomes.

The Lewis Lung Carcinoma (LLC) cell line was established from the lung of a C57BL/6 mouse bearing a lung tumor. LLC are used to create a syngeneic mouse lung cancer model, meaning that it is a mouse lung cancer model that involves a transplant into a host which is immunologically intact. Syngeneic tumor models have proven to be useful in predicting clinical benefit of therapy in preclinical experiments. In vitro, the cells are anaplastic, varying in size and shape; and appear to have little cytoplasm. The nuclei of the cells are highly distorted and prominent. In vivo, subcutaneously injected tumors are highly vascularized and metastasized to a variety of different sites but usually target the lungs. In cases of lung metastasis, large tumor masses often become necrotic and can hemorrhage. Our growth studies show slow onset with rapid growth starting at 14 days post-implantation. Control animals stay on study for 25-30 days prior to reaching euthanasia criteria.  This results in a model which can facilitate up to a three-week dosing window for test agents to elicit their anti-tumor activity.

LLC Mouse Lung Cancer Model Validation with Cyclophosphamide.  2.5 x 10Lewis Lung Carcinoma (mouse non-small cell lung carcinoma; derived from C57BL/6 mice) cells were subcutaneously injected into the rear flank of C57BL/6 mice. Once mean tumor size reached 75-100 mm3, mice were randomized int groups and treated with chemotherapy.  Tumor growth volume was monitored approximately twice / week using calipers (Data are mean± SEM; n=15).

LLC cells have been previously reported to be susceptible to cyclophosphamide.

The LLC Mouse Lung Cancer Model can accommodate a variety of study designs.  In addition to tumor volume a variety of additional physiological parameters and biomarkers, such as cytokine levels,  can be incorporated into the study design.  Study durations can range from 4 to 6 weeks.